EUVIMEDOntdek EUVIMED
Open access · CC BY-NC-ND 4.0

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls

Daniela S Allende, Oscar Cummings, Alice L Sternberg, Cynthia A Behling, Danielle Carpenter, Ryan M Gill, Cynthia D Guy, Matthew M Yeh, Samer Gawrieh iD, Richard K Sterling, Susanna Naggie, Rohit Loomba and 9 more

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18236 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Daniela S Allende and 20 co-authors. Institution: Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: HIV Infections, Liver Cirrhosis. Cited 17 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCATS NIH HHS, NIDDK NIH HHS, Intramural Research Program of the National Institutes of Health.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Background

Metabolic dysfunction‐associated steatotic liver disease (MASLD) is common in people with HIV (PWH). The morphological spectrum of MASLD compared to matched controls and of the correlation between the NAFLD activity score (NAS) and fibrosis stage in PWH remains unknown.

Methods

Overall, 107 liver biopsies from PWH with MASLD (MASLD‐PWH) were matched to 107 biopsies from individuals with MASLD and without HIV (MASLD controls) on age at biopsy, race/ethnicity, sex, type 2 diabetes, body mass index (BMI) and alanine aminotransferase (ALT) level. Biopsies were scored using NAS.

Results

Compared to MASLD‐controls, MASLD‐PWH had lower steatosis grade (OR: 0.65, 95% CI: (0.47–0.90), p = 0.01), lower lobular inflammation grade (OR: 0.55, 95% CI: (0.34–0.89), p = 0.02), less portal inflammation (OR: 0.42, 95% CI: (0.25–0.72), p = 0.002) and less ballooned hepatocytes (OR: 0.60, 95% CI: (0.41–0.88), p = 0.01). Thus, NAS was lower in MASLD‐PWH (OR: 0.69, 95% CI: (0.56–0.85), p < 0.001) than in MASLD controls. There was a trend towards lower prevalence of steatohepatitis in MASLD‐PWH (OR: 0.84, 95% CI: (0.68–1.03), p = 0.09). A multivariate analysis demonstrated that MASLD‐PWH cases had significantly less steatosis (OR: 0.66, p = 0.03), portal inflammation (OR: 0.34, p = 0.001) and ballooned hepatocytes (OR: 0.55, p = 0.01), yet higher stage fibrosis (OR: 1.42, p = 0.03) compared to MASLD controls.

Conclusion

The NAS and histological drivers of fibrosis (e.g. inflammation and hepatocyte ballooning) are less pronounced in MASLD‐PWH, and yet fibrosis stage was generally higher when compared to matched controls with MASLD without HIV. This suggests HIV‐specific factors beyond hepatic necroinflammation may contribute to fibrosis progression in MASLD‐PWH.

Subjects

MeSH terms (MEDLINE)

HIV InfectionsLiver CirrhosisHumansMaleFemaleMiddle AgedAdultBiopsyCase-Control StudiesLiverFatty LiverSeverity of Illness IndexNon-alcoholic Fatty Liver DiseaseBody Mass Index

Authors and institutions

  • Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Pacific Rim Pathology, San Diego, California, USA.
  • Saint Louis University, St. Louis, Missouri, USA.
  • University of California San Francisco, San Francisco, California, USA.

ORCID profiles: Samer Gawrieh, Jennifer C Price, Naga P Chalasani

Funding

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • Intramural Research Program of the National Institutes of Health
  • Intramural NIH HHS
  • NCI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Cancer Institute

Cite

APA

Allende, D. S., Cummings, O., Sternberg, A. L., Behling, C. A., Carpenter, D., Gill, R. M., Guy, C. D., Yeh, M. M., Gawrieh, S., Sterling, R. K., Naggie, S., Loomba, R., Price, J. C., McLaughlin, M., Hadigan, C., Crandall, H., Belt, P., Wilson, L., Chalasani, N. P., …, & HIV NASH and NASH Clinical Research Groups (2024). MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18236

Vancouver

Allende DS, Cummings O, Sternberg AL, Behling CA, Carpenter D, Gill RM, et al. MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18236

BibTeX
@article{Allende2024,
  author = {Allende, Daniela S and Cummings, Oscar and Sternberg, Alice L and Behling, Cynthia A and Carpenter, Danielle and Gill, Ryan M and Guy, Cynthia D and Yeh, Matthew M and Gawrieh, Samer and Sterling, Richard K and Naggie, Susanna and Loomba, Rohit and Price, Jennifer C and McLaughlin, Mary and Hadigan, Colleen and Crandall, Holly and Belt, Patricia and Wilson, Laura and Chalasani, Naga P and Kleiner, David E and HIV NASH and NASH Clinical Research Groups, HIV NASH and NASH Clinical Research Groups},
  title = {MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18236}
}
Start for free →